Federal Research Agency
Appears in 2 stories
Designated to administer $50 million in psychedelic research funding, matched by state investments
For 55 years, the federal government classified psilocybin, MDMA, LSD, and ibogaine as Schedule I substances. On April 18, 2026, President Trump signed an executive order 'Accelerating Medical Treatments for Serious Mental Illness' directing the FDA to expedite clinical trials of those substances for PTSD in veterans.
Updated May 31
Investing over $500 million in cancer-related projects
Cancer death rates in the United States peaked in 1991 at 215 deaths per 100,000 people and have since fallen 34%, averting an estimated 4.5 million deaths. The decline accelerated from about 1% annually in the 1990s to 2% annually by 2015-2020, driven by plummeting smoking rates, earlier detection through screening, and advances in targeted therapies and immunotherapy.
Updated May 22
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
